Cystic Fibrosis

Committed to Global Cystic Fibrosis Research

With any cystic fibrosis program, building and maintaining strong relationships is critical. For this reason, we make a concerted effort to keep our cross-functional cystic fibrosis study teams together over the course of multiple studies—aiding development of our therapeutic indication expertise and strengthening our relationships with key opinion leaders and clinical sites in North America and Europe.

Why Choose Rho?

Rho understands what it takes to successfully execute global cystic fibrosis studies. Not only have we conducted studies of both pulmonary and gastrointestinal outcomes through inpatient and outpatient studies, we also have a comprehensive understanding of both the Cystic Fibrosis Foundation Therapeutics Development Network (CFF TDN) and the European Cystic Fibrosis Society (ECFS) Clinical Trials Network and their protocol assessment and feasibility processes. We have experience coordinating standard of care with study-specific procedures and assessments, interacting with multidisciplinary care teams, Non-CFTR modulator studies, and working with the CFF TDN data safety monitoring board (DSMB).

Expertise in Action

Following study start-up for a Phase III cystic fibrosis study, the Cystic Fibrosis Foundation Therapeutics Development Network conducted a survey of participating clinical sites to assess their satisfaction with Rho.
Some highlights include:

  • 100% of sites ranked Rho as good or excellent for 6 of the 7 questions asked.
    For the seventh question, 90% of sites ranked Rho as good or excellent.
  • On all questions, Rho scored higher than the CFF TDN average.

Rho has experience with

  • CF Gene Therapy
  • Aerosolized Products
  • Oral Therapies
  • Inpatient
  • PK
  • PERT/GI
  • Anti-infectives

Expertise with Common CF Assessments & Endpoints

  • CFA
  • CFQ-R
  • CNA
  • FEV1/FVC
  • MCC
  • Sputum Collection

Our Expertise

Relationships with

40+

CF research centers (both CFF TDN, ECFS CTN, and non-CFF TDN and ECFS CTN sites).

In the past 3 years, we have conducted

10 studies and 2 marketing application efforts.

Some of the Sites We’ve Worked With Include

  • University of Alabama; Birmingham, AL
  • Johns Hopkins University; Baltimore, MD
  • Virginia Commonwealth University; Richmond, VA
  • Northwestern University; Chicago, IL
  • University of California San Diego; San Diego, CA
  • University Hospitals Cleveland Medical Center; Cleveland, OH
  • Children’s Hospital Colorado; Aurora, CO
  • University of Kansas Medical Center; Kansas City, KS
  • Nationwide Children’s Hospital; Columbus, OH
  • National Jewish Health; Denver, CO
  • University of Florida; Gainesville, FL
  • University of North Carolina at Chapel Hill; Chapel Hill, NC
  • Hershey Medical Center Pennsylvania State University; Hershey, PA
  • Boston Children’s Hospital; Boston, MA
  • University of Pennsylvania; Philadelphia, PA
  • Children’s Hospital of Pittsburgh of UPMC; Pittsburgh, PA
  • Żagiel-Med Szpital; Lublin, Poland
  • Medical University of South Carolina; Charleston, SC
  • Cassia Villa Medica ul Słoneczna; Rabka-Zdrój, Poland
  • Tüdőgyógyintézet Törökbálint; Törökbálint, Hungary
  • Podkarpacki Osrodek Pulmonologii i Alergologii; Rzeszów, Poland
  • Sanatorium “ Kamienny Potok”; Sopot, Poland
  • Hospital La Fe de Valencia,; Valencia, Spain
  • Pediatric Pulmonary Medicine: Department at the Ruth Rapport Children’s Hospital; Haifa, Israel
  • Stollery Children’s Hospital/University of Alberta; Edmonton, AB
  • Hadassah University Hospital Ein Kerem; Jerusalem, Israel
  • Magyar Imre Kórház; Ajka, Hungary
  • Unity Health Toronto – St. Michael’s Hospital; Toronto, ON
  • McGill University Health Center; Montreal, QU

CF Experience

Phase

Sites

Patients

I

5

16

I

39

60

IB

20

32

I/II

6

32

I/II

15

21

II

8

24

II

14

40

II

28

114

III

20

54

III

40

138

III

57

60

III

60

380

Rho not only gave Anthera a clear picture of how their team would fulfill the study needs but showed their knowledge and expertise of cystic fibrosis as well as the protocol in a way that made them a collaborative partner rather than a service provider.

Monica Gangal, Former VP of Clinical Operations at Anthera

Join us in our commitment to respiratory research as we passionately fight to help those affected by respiratory diseases breathe a little easier. We proudly invite you to experience Rho.

Square_Header_Image